Medicines and devices entitled for subsidy
Guidelines and best practice outlines Links to health sector organisations
Outlines from the Ministry of Health
Overview of diabetes medications Professional papers about diabetes medication
Online Pharmaceutical Schedule www.pharmac.govt.nz/healthpros/Schedule
Online Hospital Medicines List www.pharmac.govt.nz/HMLOnline.php
Pharmaceutical Schedule http://www.pharmac.govt.nz/latest/Sched.pdf
Pharmaceutical Schedule Current Update http://www.pharmac.govt.nz/latest/SU.pdf
Section H Current Update http://www.pharmac.govt.nz/latest/SectionH.pdf
SPECIAL FOODS Explanatory notes
Please see Section D of the PDF version of the Pharmaceutical Schedule
Link to PDF copies of the Pharmaceutical Schedule and updates
Pharmaceutical Schedule http://www.pharmac.govt.nz/latest/Sched.pdf
Pharmaceutical Schedule Current Update http://www.pharmac.govt.nz/latest/SU.pdf
Scbscribe to the hard copy Pharmaceutical Schedule (the link enables you to purchase a copy)
Email copy Completing this email subscription page will mean a link to a free downloadable PDF document will be sent to your nominated email address
LINK to the online Phamaceutical Schedule
The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the amount of that subsidy paid to contractors, the supplier’s price and the access conditions that may apply.
Source – New Zealand Pharmaceutical Schedule April 2013
ATTACHMENTS (printable)
PHARMAC Information Sheet # 14 – Inside the Pharmaceutical Schedule
PHARMAC Information Sheet # 6 The facts about generic medicines
Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person. Applications must be submitted to the Ministry of Health by the prescriber for the request to be processed.
(Note: Registered Nurse Diabetes Prescribers are not currently able to make Special Authority applications.)
LINKS
Special Authority Forms - www.pharmac.health.nz/tools-resources/forms/special-authority-application-forms
Blood Glucose Meters
Information for people with diabetes 2013
http://www.pharmac.health.nz/medicines/your-health/diabetes/blood-glucose-meters-changes
‘Diabetes Nurse Prescriber’ means a registered nurse practicing in diabetes health who has authority to prescribe specific diabetes medicines in accordance with regulations made under the Medicines Act 1981, and who is practicing in an approved DHB demonstration site.
Source – New Zealand Pharmaceutical Schedule April 2013
Below is the list of medicines and medical devices Registered Nurse Diabetes Prescribers can prescribe and are entitled for subsidy.
Source – PHARMAC 24 January 2013
Scroll down for the list BY THERAPEUTIC CLASS
| Chemical Name | Therapeutic Class |
| Amlodipine | Dihydropyridine Calcium Channel Blockers |
| Aspirin | Antiplatelet Agents |
| Atorvastatin | HMG CoA Reductase Inhibitors (Statins) |
| Bendrofluazide | Thiazide and Related Diuretics |
| Blood glucose diagnostic test meter | Blood Glucose Testing |
| Blood glucose diagnostic test strip | Blood Glucose Testing |
| Blood ketone diagnostic test meter | Ketone Testing |
| Candesartan | Angiotension II Antagonists |
| Captopril | ACE Inhibitors |
| Cilazapril | ACE Inhibitors |
| Cilazapril with hydrochlorothiazide | ACE Inhibitors with Diuretics |
| Diltiazem hydrochloride | Other Calcium Channel Blockers |
| Enalapril | ACE Inhibitors |
| Enalapril with hydrochlorothiazide | ACE Inhibitors with Diuretics |
| Felodipine | Dihydropyridine Calcium Channel Blockers |
| Glibenclamide | Oral Hypoglycaemic Agents |
| Gliclazide | Oral Hypoglycaemic Agents |
| Glipizide | Oral Hypoglycaemic Agents |
| Glucagon hydrochloride inj 1 mg syringe kit | Hyperglycaemic Agents |
| Hydrochlorothiazide | |
| Insulin pen needles | Insulin Syringes and Needles |
| Insulin pump accessories | Insulin Pump Consumables |
| Insulin pump infusion sets | Insulin Pump Consumables |
| Insulin pump reservoirs | Insulin Pump Consumables |
| Insulin syringes disposable with attached needle | Insulin Syringes and Needles |
| Insulin(s) | |
| Ketone blood beta-ketone electrodes test strip | Ketone Testing |
| Lisinopril | ACE Inhibitors |
| Losartan | Angiotension II Antagonists |
| Losartan with hydrochlorothiazide | Angiotension II Antagonists with Diuretics |
| Metformin | Oral Hypoglycaemic Agents |
| Nicotine | Stimulants/ADHD treatments |
| Perindopril | ACE Inhibitors |
| Quinapril | ACE Inhibitors |
| Quinapril with hydrochlorothiazide | ACE Inhibitors with Diuretics |
| Simvastatin | HMG CoA Reductase Inhibitors (Statins) |
| Sodium nitroprusside test strip | Ketone Testing |
| Trandolapril | ACE Inhibitors |
| Verapamil hydrochloride | Other Calcium Channel Blockers |
| Therapeutic Class | Chemical Name |
| ACE Inhibitors | Captopril |
| ACE Inhibitors | Cilazapril |
| ACE Inhibitors | Enalapril |
| ACE Inhibitors | Lisinopril |
| ACE Inhibitors | Perindopril |
| ACE Inhibitors | Quinapril |
| ACE Inhibitors | Trandolapril |
| ACE Inhibitors with Diuretics | Cilazapril with hydrochlorothiazide |
| ACE Inhibitors with Diuretics | Enalapril with hydrochlorothiazide |
| ACE Inhibitors with Diuretics | Quinapril with hydrochlorothiazide |
| Angiotension II Antagonists | Candesartan |
| Angiotension II Antagonists | Losartan |
| Angiotension II Antagonists with Diuretics | Losartan with hydrochlorothiazide |
| Antiplatelet Agents | Aspirin |
| Blood Glucose Testing | Blood glucose diagnostic test meter |
| Blood Glucose Testing | Blood glucose diagnostic test strip |
| Dihydropyridine Calcium Channel Blockers | Amlodipine |
| Dihydropyridine Calcium Channel Blockers | Felodipine |
| HMG CoA Reductase Inhibitors (Statins) | Atorvastatin |
| HMG CoA Reductase Inhibitors (Statins) | Simvastatin |
| Hyperglycaemic Agents | Glucagon hydrochloride inj 1 mg syringe kit |
| Insulin Pump Consumables | Insulin pump accessories |
| Insulin Pump Consumables | Insulin pump infusion sets |
| Insulin Pump Consumables | Insulin pump reservoirs |
| Insulin Syringes and Needles | Insulin pen needles |
| Insulin Syringes and Needles | Insulin syringes disposable with attached needle |
| Ketone Testing | Blood ketone diagnostic test meter |
| Ketone Testing | Ketone blood beta-ketone electrodes test strip |
| Ketone Testing | Sodium nitroprusside test strip |
| Oral Hypoglycaemic Agents | Glibenclamide |
| Oral Hypoglycaemic Agents | Gliclazide |
| Oral Hypoglycaemic Agents | Glipizide |
| Oral Hypoglycaemic Agents | Metformin |
| Other Calcium Channel Blockers | Diltiazem hydrochloride |
| Other Calcium Channel Blockers | Verapamil hydrochloride |
| Stimulants/ADHD treatments | Nicotine |
| Thiazide and Related Diuretics | Bendrofluazide |
| Hydrochlorothiazide | |
| Insulin(s) |
Note:
DIABETES MEDICATION UNFUNDED BY PHAMAC and not prescribed by Registered Nurse Diabetes Prescribers
At Sept 2013
Incretins or Glucagon-like peptide-1 agonists (GLP-1) Exenatide (Byetta)
DPP4 inhibitors – Sitagliptin (Januvia)
Below is the list of Registered Nurse Diabetes Prescribers. More details of their individual registrations can be found on the Nursing Council of New Zealand website www.nursingcouncil.org.nz
|
District Health Board |
Registered Nurse Practising in Diabetes Health |
NCNZ Registration Number |
|
|
Northland DHB |
Bronwyn |
Henderson |
124928 |
|
Northland DHB |
Amy |
Savage |
152390 |
|
Northland DHB |
Rosemarie Adrienne |
Coats |
148277 |
|
Auckland DHB |
Patricia |
Ball |
052157 |
|
Auckland DHB |
Mele |
Kaufusi |
114474 |
|
Auckland DHB |
Jennifer |
Somerville |
060927 |
|
Auckland DHB |
Melanie |
Lubeck |
151268 |
|
Auckland DHB |
Jane |
Wilkinson |
124468 |
|
Auckland DHB |
Diane |
Bermingham |
137642 |
|
Counties Manukau DHB |
Kathryn |
Smallman |
148492 |
|
Counties Manukau DHB |
Roberta |
Milne |
114488 |
|
Counties Manukau DHB |
Sally |
Morgan |
060775 |
|
Counties Manukau DHB |
Claire |
O'Brien |
153805 |
|
Hawkes Bay DHB |
Andrea |
Rooderkerk |
117987 |
|
Hawkes Bay DHB |
Heather |
Charteris |
117839 |
|
Hawkes Bay DHB |
Tony |
Loversuch |
138813 |
|
MidCentral DHB |
Mary |
Meendering |
108408 |
|
MidCentral DHB |
Alison |
Fellerhoff |
064890 |
|
MidCentral DHB |
Kerrie |
Skeggs |
112025 |
|
MidCentral DHB |
Lois |
Nikolajenko |
049016 |
|
Whanganui DHB |
Delia |
Williams |
147694 |
|
Hutt Valley DHB |
Anne-Marie |
Heffernan |
148903 |
|
Hutt Valley DHB |
Hazel |
Phillips |
160328 |
|
Hutt Valley DHB |
Lynette |
McPherson |
136832 |
|
Southern DHB |
Sharon |
Sandilands |
110421 |
Source – PHARMAC 24 January 2013
Nurse practitioners are expert nurses who work within a specific area of practice that requires advanced knowledge and skills. They practise both independently and in collaboration with other health care professionals to promote health, prevent disease and to diagnose, assess and manage people’s health needs.
Helen Snell MidCentral DHB
Pauline Giles MidCentral DHB
Isabel Raiman Bay of Plenty DHB
ATTACHMENTS (printable)
|
PHARMAC |
The Pharmaceutical Management Agency (PHARMAC) is the New Zealand Government agency that decides, on behalf of District Health Boards, which medicines and related products are subsidised for use in the community and, in some cases, funded in public hospitals. |
|
|
Health Quality and Safety Commission |
The Health Quality & Safety Commission was established under the New Zealand Public Health & Disability Amendment Act 2010 to ensure all New Zealanders receive the best health and disability care within our available resources. |
|
|
Medical Council of New Zealand |
The Medical Council registers doctors in of New Zealand and caries responsibilities in the areas of standards, conduct and competence. |
|
|
Medsafe |
Medsafe is the New Zealand Medicines and Medical Devices Safety Authority. We are responsible for the regulation of medicines and medical devices in New Zealand. We ensure that medicines and medical devices are acceptably safe. |
|
|
Ministry of Health |
The Government's principal advisor on health and disability: improving, promoting and protecting the health of all New Zealanders. |
|
|
National Health IT Board |
The role of the IT Health Board is to provide leadership on the implementation and use of information systems across the health and disability sector. The IT Health Board is a sub-committee of the National Health Board and is charged with ensuring that health sector policy is supported by appropriate health information and IT solutions. |
|
|
New Zealand Nurses Organisation (NZNO) |
The New Zealand Nurses Organisation is a professional and industrial organisation representing approximately 46,000 members in all areas of the health service. |
|
|
Nursing Council of New Zealand (NCNZ) |
The Nursing Council of New Zealand registers nurses and makes sure they are 'competent and fit' to practise. The Nursing Council's role and responsibilities are outlined in the Health Practitioners Competence Assurance Act 2003. |
|
|
New Zealand Society for the Study of Diabetes (NZSSD) |
NZSSD is the national advisory body on scientific and clinical diabetes care and standards. NZSSD's objectives are to promote the study of diabetes and the best standards of care of diabetes in New Zealand. It also provides the national reference source in the subject. |
|
|
The New Zealand Formulary (NZF) |
The NZF is based on the British National Formulary (BNF) and specifically adapted for New Zealand. It is a resource for healthcare professionals with information about medicines that are used in New Zealand. |
|
|
NZ Universal List of Medicines (NZULM) |
NZULM combines standardised medicine descriptions from the New Zealand Medicines Terminology (NZMT) with information from Medsafe and the PHARMAC. |
ATTACHMENT (for print)
Health Quality & Safety Commission National Medication Chart - Toolkit-Information-Leaflet.pdf
|
Prescription charges |
|
|
Pharmaceutical Subsidy Card The Pharmaceutical Subsidy Card (PSC) allows the cardholder and named family members to pay a lower amount on government prescription charges. |
|
|
Prescription Charges (tear-off pad, plus ordering) |
ATTACHMENTS (to print)
Most people with type 2 diabetes need medications for a range of other diabetes related medical issues e.g. control of complications or reduction of risk complications.
Three major factors:
Usually within a year of diagnosis there is a total lack of insulin production. Therefore, all people with type 1 diabetes need to be treated with insulin from either the day of diagnosis, or within a fairly short time of diagnosis.
Because people with type 1 diabetes don’t make any of their own insulin, they are said to be ‘insulin deficient’. They do not require blood glucose lowering tablets, insulin is sufficient.
Occasionally people with type 1 diabetes who are obese may benefit from an insulin sensitiser as well as insulin – in this case the sensitiser would usually be Metformin.
In type 2 diabetes there is usually a combination of decreased insulin production, and insulin resistance. Treatment often begins with diet, exercise and weight loss management. If these strategies are not sufficient to achieve healthy blood glucose levels after three months (NZGG, 2011), people with type 2 diabetes usually move first onto tablets.
When, or if, tablet therapy fails to help them achieve healthy blood glucose levels, they then require insulin therapy, often in combination with tablets.
The aim of insulin therapy in type 1 diabetes is to replace the supply of insulin the patient’s pancreas is no longer producing.
The aim of insulin therapy in type 2 diabetes is to supplement the supply of insulin that the patient’s pancreas is still producing.
Having healthy blood pressure has been shown to be very important in reducing the risk of most diabetes complications. The NZ Guidelines Group recommend that people with early kidney damage should be started on an ACE inhibitor or Angiotensin 2 receptor-blocker (ARB), irrespective of blood pressure levels. These medications can slow diabetes related kidney damage. ACE I and ARB can also slow retinopathy.
The current recommended blood pressure for those with diabetes is less than, or equal to, 130 / 80mmHg. This target should be aggressively pursued in those with diabetes, as the benefits of normotension (normal) are very significant in this group of patients.
Improved control of cholesterol can reduce cardiovascular complications by 20 – 50 %. Below are the current recommended lipid levels for people with diabetes
NEW ZEALAND PRIMARY CARE HANDBOOK 2012
Optimal levels (targets) for people with known cardiovascular disease, or cardiovascular risk
|
Known cardiovascular disease or cardiovascular risk > 15% or diabetes |
|
|
Lipids |
|
|
Total cholesterol |
< 4.0 mmol/L |
|
LDL cholesterol |
< 2.0 mmol/L |
|
HDL cholesterol |
≥ 1.0 mmol/L |
|
TC:HDL ratio |
< 4.0 |
|
Triglycerides |
< 1.7 mmol/L |
Please click on the title to view and print the document.
SIGN Scottish Intercollegiate Guidelines Network: Management of Diabetes
ADA Standards of Medical Care in Diabetes 2013
NEMJ Effects of Intensive Glucose Lowering in Type 2 Diabetes.pdf
NMJ A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes.pdf
NMJ Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes.pdf
Online Pharmaceutical Schedule www.pharmac.govt.nz/healthpros/Schedule
Online Hospital Medicines List www.pharmac.govt.nz/HMLOnline.php